ReviewVaccine2003
How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past.
Review in Vaccine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Systematic Review of the Literature and Challenges.AIDS research and human retroviruses · 2021Pooled it
- Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies.Frontiers in immunology · 2023Article
- High-precision and cost-efficient sequencing for real-time COVID-19 surveillance.Scientific reports · 2021Article
- COVID-19 and AIDS: Outcomes from the coexistence of two global pandemics and the importance of chronic antiretroviral therapy.Journal of medical virology · 2021Article
- Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends".Frontiers in immunology · 2020Review
- Discovery of T-cell Driven Subunit Vaccines from Zika Virus Genome: An Immunoinformatics Approach.Interdisciplinary sciences, computational life sciences · 2017Article
- Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases.Expert review of vaccines · 2015Review
- Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?Human vaccines & immunotherapeutics · 2013Review
- Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein.Virology · 2005Article
- B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.Journal of virology · 2005Article
- Treatment and vaccines for severe acute respiratory syndrome.The Lancet. Infectious diseases · 2005Review
- Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice.Biochemical and biophysical research communications · 2005Article
- Molecular mechanisms of severe acute respiratory syndrome (SARS).Respiratory research · 2005Review
- Specific immunoglobulin g antibody detected in umbilical blood and amniotic fluid from a pregnant woman infected by the coronavirus associated with severe acute respiratory syndrome.Clinical and diagnostic laboratory immunology · 2004Article
- A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.International immunology · 2004Article
- Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.The Journal of infectious diseases · 2004Article
- SARS corona virus peptides recognized by antibodies in the sera of convalescent cases.Virology · 2004Article
- Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.Journal of virology · 2004Article
- PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2004Article
- Role of interferons in the treatment of severe acute respiratory syndrome.Expert opinion on biological therapy · 2004Review
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A remarkable collaborative effort coordinated by the severe acute respiratory syndrome (SARS) team at WHO resulted in discovery of the etiologic agent of severe acute respiratory syndrome less than 2 months after the announcement of global alert. The development of a vaccine to prevent SARS should be pursued with the same urgency and cooperative spirit, as SARS is highly lethal and, if not controlled during the first few generations of transmission, is likely to become endemic in regions of the world where health-care infrastructure is underdeveloped and epidemiological control measures are weak. The scientific community already learned many important lessons from HIV vaccine development; these should be heeded. For example, consideration should be given to the development of a vaccine that will protect across regional strains of SARS, as the newly emergent coronavirus SARS-coronavirus (SARS-CoV) is proving to be variable and may be mutating in response to immune pressure. SARS-specific research reagents should also be collected and shared. These would include SARS peptides, adjuvants, DNA vaccine vectors and clinical grade viral vectors. Rapidly developing a collaborative approach to developing a SARS vaccine that will be both effective and safe is the only way to go. This article reviews parallels between HIV and SARS and proposes an approach that would accelerate the development of a SARS vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.